Draw/line
Education and research purposes only, not medical advice. Unapproved compounds are not for human consumption. Check every result with your prescriber. Disclaimer Research and education only. Not medical advice. Disclaimer
Home / Compounds / Cagrilintide

Cagrilintide

Cagrilintide and CagriSema: Novo Nordisk's amylin analog, its pending FDA review, why it cannot be compounded, trial evidence and risks.

Investigational, under FDA review · Evidence grade B · Reviewed

Not approved by the FDA for human use. Not for human consumption. This page describes Cagrilintide only to explain its regulatory status, what has been studied and its known risks. Drawline does not recommend obtaining or using it. Disclaimer

Get an email when FDA, HHS or anti-doping status changes for Cagrilintide. Free account.
Approved and studied uses
  • Under FDA review, not approvedWeight managementCagriSema, under FDA review; not approved
Training and drug testingCheck the rules

WADA does not name cagrilintide; as a substance with no government approval for human use it may fall under S0 (non-approved substances), while semaglutide itself is not prohibited.

Drug-tested athletes can look up any substance on Global DRO, run by national anti-doping agencies. Supplements can contain banned substances that are not on the label. Drawline does not suggest when to train or inject.

Cagrilintide (CagriSema (cagrilintide with semaglutide), amylin analog). Long-acting amylin analog.

BInvestigational, under FDA review. Evidence grade B: human trials, narrow or pending approval.

What is Cagrilintide?

Cagrilintide is a lab-made, long-acting version of amylin, a hormone released with insulin that slows stomach emptying and increases fullness. Novo Nordisk is developing it mainly in a once-weekly combination with semaglutide called CagriSema.

Is Cagrilintide FDA-approved?

Neither cagrilintide nor CagriSema is FDA-approved as of November 2026. Novo Nordisk submitted a New Drug Application for CagriSema for chronic weight management in December 2025 and has said it expects an FDA decision in the fourth quarter of 2026. FDA has stated that cagrilintide cannot be used in compounding under federal law, so any product sold now as cagrilintide or CagriSema is not FDA-reviewed.

What does the evidence show for Cagrilintide?

Large phase 3 trials exist. In REDEFINE 1 (published in NEJM in 2025), adults with obesity on CagriSema lost about 20% of body weight at 68 weeks versus 3% on placebo; in a 2026 head-to-head trial CagriSema did not meet its goal of matching tirzepatide. Data on cagrilintide alone come mostly from phase 2 and the comparison arms of these trials.

What are the known risks of Cagrilintide?

The most common side effects in trials were nausea, vomiting, diarrhea and constipation, which are typical of drugs that slow digestion. Because it is combined with semaglutide, CagriSema would be expected to carry semaglutide's warnings, including its boxed warning on thyroid C-cell tumors, but no label exists yet. Unapproved products sold online carry unknown purity and dose. WADA does not name cagrilintide; as a substance with no government approval for human use it may fall under S0 (non-approved substances), while semaglutide itself is not prohibited.

How is Cagrilintide measured?

A powder vial: enter the amount in the vial and the water added, and the calculator shows the syringe units for a prescribed dose. Products sold online as "research use only" have no assurance of identity, dose or sterility. The calculator can do the arithmetic for any vial, but it cannot tell you what is actually in one.

Sources: FDA: Concerns with unapproved GLP-1 drugs used for weight loss; Novo Nordisk Form 6-K, H1 2026 financial report (SEC); PubMed: Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes (REDEFINE 2); ACC journal scan: REDEFINE 1 and REDEFINE 2. This profile does not recommend any dose or use.

For research and educational use. Not medical advice. Regulatory status changes, so confirm the current position with FDA or a licensed professional.

Spot a mistake or an out-of-date fact? Report an error. We check every report against the sources.